Editorials in major journals may provide an important review of opinion regarding diabetes and pharmacotherapy of diabetes as well as the nature of treatment. Many years ago Siperstein argued against support of rigid glycemic control. According to Siperstein [1, 2] most studies on better glycemic control were inconclusive. This left the clinicians with the impression that complications were related to genetic patterns and not to the phenotypic risk factors occurring with diabetes. Later he argued that the muscle capillary basement membrane could be influenced by the level of blood glucose, but whether this was related also to other organs such as the kidney and the retina was in doubt, thus arguing against results in the important work of Østerby. I believe that this really influenced the clinical practice in the USA for many years.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Siperstein MD, Foster DW, Knowles HC. Control of blood glucose and diabetic vascular disease. N Engl J Med 1977;296(1):1060–1063.
Siperstein MD. Diabetic microangiopathy and the control of blood glucose. N Engl J Med 1983;309:1577–1579.
Gerich JF. Role of growth hormone in diabetes mellitus. N Engl J Med 1984;310(13):848–850.
Fathman CG, Myers BD. Cyclosporine therapy for autoimmune disease. N Engl J Med 1992; 327(4):271–273.
Gale EAM. Can we change the course of beta-cell destruction in type 1 diabetes? N Engl J Med 2002;346:1740–1741.
Lasker RD. The diabetes control and complications trial – implications for policy and practice. New Engl J Med 1993;329:1035–1036.
William T and Cefalu MD. Glycemic control and cardiovascular disease – should we reassess clinical goals? New Engl J Med 2005;353:2707–2709.
Mogensen CE. Combined high blood pressure and glucose in type 2 diabetes: double jeopardy. British trials show clear effects of treatment, especially blood pressure reduction. Br Med J; 1998; 317:693–694.
Remuzzi G. Slowing the progression of diabetic nephropathy. N Engl J Med 1993;329:1496–1497.
Viberti CG. A glycemic threshold for diabetic complications? N Engl J Med 1995;332:1293–1294.
Parving H-H. Initiation and progression of diabetic nephropathy. N Engl J Med 1996;335:1682–1683.
Crofford OB. Metformin. N Engl J Med 1995;333:588–589.
Imura H. A novel antidiabetic drug – troglitazone – reason for hope and concern. N Engl J Med 1998;338:908–909.
Luzi L. Pancreas Transplantation and diabetic complications. N Engl J Med 1998;339:115–117.
Robertson RP. Successful islet transplantation for patients with diabetes – fact or fantasy? N Engl J Med 2000;343:289–290.
Bakris GL. Antihypertensive therapy and the risk of type 2 diabetes mellitus. N Engl J Med 2000;342:969–970.
Ingelfinger JR, Solomon CG. Angiotensin-converting-enzyme inhibitors for impaired glucose tolerance – is there still hope? N Engl J Med 355:1608–1610.
Jamerson KH, Bakris GL, Wun CC. Rationale and design of the avoiding cardiovascular events through combination therapy in patients living with systolic hypertension (ACCOMPLISH) trial. Am J Hypertens 2004;17:793–801.
Hostetter TH. Prevention of end-stage renal disease due to type 2 diabetes. N Engl J Med 2001;345:910–911.
Mitch WE. Treating diabetic nephropathy is – are there only economic issues. N Engl J Med 2004;35348:1934–1936.
Ritz E. Albuminuria and vascular damage – the vicious twins. N Engl J Med 2003;348:2349–2351.
Solomon CG. Reducing cardiovascular risk in type 2 diabetes. N Engl J Med 2003;348:457–459.
Yki-Järvinen H. The PROactive study: some answers, many questions. The Lancet 2005;366:1241–1242.
Nathan DM. Thiazolidinediones for initial treatment of type 2 diabetes. N Engl J Med 2006;355:2477–2480.
Nathan DM. Finding new treatments for diabetes – how many, how fast… how good? N Engl J Med 356:437–440.
Berry C, Tardif JC, Bourassa MG. Coronary heart disease in patients with diabetes. part 1: recent advances in prevention and noninvasive management. J Am Coll Cardiol 2007;49:631–642.
Berry C, Tardif JC, Bourassa MG. Coronary heart disease in patients with diabetes. part ii: recent advances in coronary revascularization. J Am Coll Cardiol 2007;49:643–656.
Short R. Fracture risk is a class effect of glitazones. Br Med J 2007;334:551.
Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007;356:xx–xx.
Singh S, Loke YK, Furberg CD. Thiazolidinediones and Heart Failure: A Teleo-Analysis. Diabetes Care 2007; DOI:10.2337/dc07–0141.
Home PD, Pocock SJ, Beck-Nielsen H, et al. Rosiglitazone evaluated for cardiovascular outcomes – an interim analysis. N Engl J Med 2007;DOI:0.1056/NEJMoa073394.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2007 Springer Science+Business Media, LLC
About this chapter
Cite this chapter
Mogensen, C.E. (2007). Pharmacotherapy of Diabetes. In: Mogensen, C.E. (eds) Pharmacotherapy of Diabetes: New Developments. Springer, Boston, MA. https://doi.org/10.1007/978-0-387-69737-6_28
Download citation
DOI: https://doi.org/10.1007/978-0-387-69737-6_28
Publisher Name: Springer, Boston, MA
Print ISBN: 978-0-387-69736-9
Online ISBN: 978-0-387-69737-6
eBook Packages: MedicineMedicine (R0)